These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16613415)

  • 1. Erythropoietin claims monitoring policy: implications for clinical practice.
    Messana T
    Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
    Messana T
    Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 4. ESA payment changes: chasing a moving target.
    Sargent JA
    Nephrol News Issues; 2008 Jan; 22(1):36-7. PubMed ID: 18271437
    [No Abstract]   [Full Text] [Related]  

  • 5. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
    Besarab A; McCrea JB
    ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
    [No Abstract]   [Full Text] [Related]  

  • 6. Rebates for anti-anemia drugs draw response from FDA, CMS.
    Sipkoff M
    Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients.
    Ofsthun NJ; Lazarus JM
    Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
    Wish JB
    Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
    Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
    Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C
    Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taking a subq approach to EPO: experience in the clinic.
    Wish J
    Nephrol News Issues; 2007 Oct; 21(11):68. PubMed ID: 17970511
    [No Abstract]   [Full Text] [Related]  

  • 12. Anemia management in dialysis: Why the FDA and CMS have it right (and how KDIGO got it wrong).
    Coyne DW
    Nephrol News Issues; 2013 Feb; 27(2):16, 18, 20. PubMed ID: 23469454
    [No Abstract]   [Full Text] [Related]  

  • 13. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report from the University Healthsystem Consortium.
    Int J Technol Assess Health Care; 1999; 15(2):437-8. PubMed ID: 10507201
    [No Abstract]   [Full Text] [Related]  

  • 15. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing anemia: what do we do now?
    Neumann ME
    Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
    [No Abstract]   [Full Text] [Related]  

  • 17. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
    Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding epoetin use: databases or clinical trials?
    Roger SD
    Nephrology (Carlton); 2007 Apr; 12(2):118-9. PubMed ID: 17371331
    [No Abstract]   [Full Text] [Related]  

  • 19. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Has economics overshadowed our clinical approaches to EPO?
    Sullivan JD
    Nephrol News Issues; 2007 Jul; 21(8):56, 58-9, 68. PubMed ID: 17688233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.